Natpar - supply shortage
Ongoing
parathyroid hormone
ShortageHuman
Shortage information
There is an ongoing shortage of Natpar in the EU/EEA (European Economic Area). The shortage started in 2022 due to unresolved manufacturing challenges (related to particle formation) which led to the discontinuation of all strengths at the end of 2024.
The company has continued to supply any remaining stock where available but will cease distribution completely by 1 July 2026, when the medicine’s marketing authorisation will be withdrawn.
For further information on the use of the medicine please refer to the medicine’s overview page.
The company for Natpar, Takeda, had been experiencing manufacturing challenges since 2022 and discontinued manufacturing of all strengths of the medicine at the end of 2024.
The discontinuation affects all Member States where the product was previously marketed: Austria, Belgium, Cyprus, Czechia, Finland, Germany, Greece, Hungary, Italy, the Netherlands, Norway, Portugal, Romania, Spain and Sweden.
EMA is closely monitoring the supply situation of Natpar and alternative medicines and is engaging with Takeda to manage the impact of the discontinuation.
Monitoring is carried out by EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) and shortages working party (Medicines Shortages Single Point of Contact – SPOC - working party). For further information see ‘related information’.
- Healthcare professionals should not prescribe Natpar to new patients.
- For existing patients and while stocks last, healthcare professionals should consider prescribing a reduced dose.
- Patients should be switched in time to a suitable alternative therapy, where appropriate and in line with relevant clinical guidelines, including the revised European Society of Endocrinology Clinical Practice Guideline: Treatment of Chronic Hypoparathyroidism in Adults (notes).
- A medicine shortage communication (MSC) with detailed guidance has been sent to healthcare professionals in affected Member States and is also published on the EMA website. link to DHPC will be added automatically at time of publication
- For additional information on the shortage consult your country’s shortage register or contact your national competent authority.
- You may also contact relevant healthcare professional organisations for further information. A list of European not-for-profit organisations with which EMA engages can be found on the EMA website.
Notes: Revised European Society of Endocrinology Clinical Practice Guideline: Treatment of Chronic Hypoparathyroidism in Adults. Jens Bollerslev, Ottilia Buch et al. European Journal of Endocrinology, Volume 193, Issue 5, November 2025, Pages G83–G112
- Doctors will not start any new patients on Natpar. In case you are already taking it, you may receive a reduced dose while remaining stock is available, or your doctor may recommend another suitable treatment.
- You are advised to contact your pharmacy or doctor well before your current supply runs out.
- Your doctor will closely monitor blood calcium levels and may need to adjust the doses of vitamin D and calcium supplements.
- In case you have any questions, you should speak to your doctor or pharmacist.
- For additional information, you should consult your country’s shortage register or contact your national competent authority.
- You may also contact relevant patients’ organisations for further information or support. A list of European not-for-profit organisations that EMA engages with can be found on the EMA website.
Key facts
- Medicines affected
- Natpar
- Supply shortage status
- Ongoing
- International non-proprietary name (INN) or common name
- parathyroid hormone
- Therapeutic area (MESH)
- Hypoparathyroidism
- Pharmaceutical forms affected
- Powder and solvent for solution for injection
- Strengths affected
- 100 micrograms/dose
- 75 micrograms/dose
- 50 micrograms/dose
- 25 micrograms/dose
- Availability of alternatives
- Yes
Key dates
- First published
- Last updated